The expression of cancer stem cells and its effects on the propensity for recurrence and metastasis in bladder cancer: a systematic review Agus Rizal Ardy Hariandy Hamid^{1*}, Yasmina Zahra Syadza¹, Oliver Emmanuel Yausep¹, Roberto Bagaskara Indy Christanto¹, Bayu Hernawan Rahmat Muharia¹, Chaidir Arif Mochtar¹ ¹ Department of Urology, Faculty of Medicine Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta * Corresponding author Email: rizalhamid.urology@gmail.com (RZ) Running title: Cancer stem cells as bladder cancer recurrence and metastasis marker

Abstract

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Bladder cancer is one of the most frequent cancers of the urinary tract, associated with high recurrence rates and metastasis. Cancer stem cells (CSCs) are a subpopulation of cancer cells characterized by high self-renewal and differentiation capacities, resulting in increased cancer recurrence, larger tumor size, higher rates of metastasis, higher resistance to treatment, and overall poorer prognosis. This study aimed to evaluate the role of CSCs as a prognostic tool to predict the risks of metastasis and recurrence in bladder cancer. A literature search was conducted across seven databases from January 2000 to February 2022 for clinical studies investigating the use of CSCs to determine the prognosis of bladder cancer. The following keywords were used: ("Bladder Cancer" OR "Transitional Cell Carcinoma" OR "Urothelial Carcinoma") AND ("Stem Cell" OR "Stem Gene") AND ("Metastasis" OR "Recurrence"). A total of 12 studies were deemed eligible for inclusion. SOX2, IGF1R, SOX4, ALDH1, CD44, Cripto-1, OCT4, ARRB1, ARRB2, p-TFCP2L1, CDK1, DCLK1, and NANOG, which were all identified as CSC markers, have been implicated in the recurrence and metastasis of tumor in bladder cancer, which played a role as prognostic factor of bladder cancer. Given the pluripotent and highly proliferative properties of CSCs. CSCs may play a role in the complex biological behavior of bladder cancer, including, but not limited to, its high rates of recurrence, metastasis, and resistance to treatment. The detection of cancer stem cell markers offers a promising approach in determining the prognosis of bladder cancer. Further studies in this area are thus warranted and may contribute significantly to the overall management of bladder cancer. **Keywords:** Cancer stem cells; Bladder cancer; Recurrency of bladder cancer; Metastasis of bladder cancer; Prognosis factor of bladder cancer

Introduction

Bladder cancer (BCa) is the most common neoplasm of the urinary tract and the fifth most prevalent malignancy worldwide. High-grade bladder tumors are more likely to progress to muscle-invasive disease and have a higher tendency to undergo distant metastasis. In contrast, low-grade tumors rarely invade the bladder musculature and metastasize. [1-3] However, both non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) have a high propensity of recurrence, with a 50–90% probability of recurrence within five years. [4] In addition, metastatic BCa is considered incurable. [5] Several established risk factors related to higher risks of disease progression include tumor grade, tumor size, and tumor multiplicity; however, these risk factors are insufficient to address important prognostic indicators such as recurrence rates and progression in individual cases. [6, 7] Thus, there is an urgent need to identify novel, more reliable prognostic factors for BCa.

Cancer stem cells (CSCs), also known as tumor-initiating cells, are a subpopulation

Cancer stem cells (CSCs), also known as tumor-initiating cells, are a subpopulation of undifferentiated yet tumorigenic cells within a neoplasm that are capable of tumor initiation, self-renewal, and proliferation, which are thought to be responsible for tumor progression, relapse, metastasis, and heterogeneity. [8, 9] CSC expressions have been identified in multiple human solid tumors, including breast, prostate, ovarian, and lung cancers, and are significantly associated with metastasis-free survival and other clinical outcomes. [10] Bladder cancer stem cells (BCSCs) were first identified using markers for isolation of normal stem cells in 2009. [11] Since then, BCSCs have emerged as a growing field of research, with genome-wide screening methods and platforms for establishing therapeutic targets for tumor-initiating cell populations. [12] A more profound

understanding of BCSCs and their effects on BCa may provide helpful prognostic tools and novel therapeutic targets. However, the clinical impacts of BCSC expressions and functions have not been fully elucidated yet. Hence, this systematic review aims to evaluate all available evidence regarding BCSCs and their roles in predicting the risks of metastasis and recurrence in BCa.

Materials and methods

Objectives

This article aims to provide a systematic review of primary clinical studies to identify the BCSCs markers, which have played a role as prognostic factors in BCa patients.

Study design

This systematic review was created in accordance with the guidelines for Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). [13] We determined inclusion criteria, data synthesis methods, and outcomes in advanced in a protocol registered with PROSPERO (CRD42021268964).

Search strategy

A literature search for clinical studies evaluating CSCs as a prognostic indicator in BCa published from January 2000 to February 2022 was conducted from several databases, such as Pubmed, Scopus, EMBASE, Science Direct, Proquest, CINAHL, and The Cochrane Library. The search following key terms used based on the PICO were applied to identify eligible publications: ("Bladder Cancer" OR "Transitional Cell Carcinoma" OR "Urothelial Carcinoma") AND ("Stem Cell" OR "Stem Gene") AND ("Metastasis" OR "Recurrence"). Initially, study titles and abstracts were screened. Subsequently, full text analysis of selected articles was done based on pre-set eligibility criteria. In addition, the reference lists of included studies were further evaluated to identify potential studies. Literature screening and analysis were undertaken separately by two independent researchers.

Eligibility criteria

Our inclusion criteria were as follows: (1) studies evaluating the impacts of BCSC expressions on BCa recurrence and/or metastasis; (2) prospective or retrospective cohort studies or case control studies; and (3) publications written in English. Animal and *in vitro* studies were excluded.

Outcomes

The primary outcomes of this systematic review are the effect of BCSC expressions toward recurrence and metastasis in BCa. In addition, survival analyses from several studies were also presented.

Data extraction

Two authors independently run the systematic search and screened the articles. From all eligible studies, data were also extracted independently, and any disagreement were resolved through discussion among all authors. Data recorded from each study were as follow: author's name, year of publication, study design, number of study's participant, intervention given to the participant, method used for gene expression analysis, outcomes (recurrence-free survival and metastasis-free), and mean or median year follow-up. The effect measures used were the hazard ratios and their respective 95% confidence intervals for both univariate and multivariate analyses.

Quality assessment

The qualities of the selected studies were assessed using the Newcastle-Ottawa Scale (NOS). Using this tool, selected studies were assessed based on three aspects: the selection of the study groups; the comparability of the groups; and the ascertainment of either the outcome of interest for case-control or cohort studies, respectively. Good quality studies have 3 to 4 stars in the selection component, 1 to 2 stars in the comparability component, and 3 stars in the outcome component. Fair quality studies have 2 stars in the

selection component, 1 to 2 stars in the comparability component, and 2 to 3 stars in the outcome component. Poor quality studies have 0 to 1 star in the selection component, 0 star in the comparability component, and 0 to 1 star in the outcome component. The quality assessment showed in Table 1.

131 Table 1. Risk of bias assessment using Newcastle Ottawa Score (NOS)

			Selection	ı (Max *)		Comparability (Max **)	Oi	utcome (Max	(*)	
No	Study	Represe ntativen ess of exposed cohort	Selection of exposed cohort	Ascertainm ent of exposure	No outcome of interest at start	Comparability of cohorts based on design or analysis	Assessmen t of outcome	Was follow up long enough for outcomes to occur	Adequacy of follow up of cohorts	Score
1	Ruan et al., 2012 [6]	*	*	*	*	*	*	*	*	8
2	Keymoosi et al., 2014 [13]	*	*	*	*	*	*	*	*	8

3	Wei et al., 2014 [14]	*	*	*	*	*	*	*	*	8
4	Senol et al., 2015 [15]	*	*	*	*	*	*	*	*	8
5	Sedaghat et al., 2016 [2]	*	*	*	*	*	*	N/A	*	7
6	Siddiqui et al., 2019 [16]	*	*	*	*	*	*	*	*	8
7	Chiu et al., 2020 [17]	*	N/A	*	*	N/A	*	N/A	*	5
8	Shen et al., 2015 [1]	*	*	*	*	**	*	*	*	9

9	Xu et al., 2015									
	[18]	*	*	*	*	*	*	*	*	8
10	Heo et al., 2019									
	[19]	*	*	*	*	*	*	N/A	*	7
11	Shaifei et al.,									
	2019 [20]	*	*	*	*	*	*	N/A	*	7
12	Kallifatidis et al.,									
	2019 [21]	*	*	*	*	*	*	*	-	7

Result

Study selection

The flow diagram in the form of PRISMA diagram for study selection is shown in (Figure 1). We included 12 clinical studies evaluating effects of BCSCs expression on tumor recurrence and/or metastasis, consisted of cohorts and case controls studies, involving at least 2230 patients (one study did not specify the sample size) with BCa and 68 non-tumor tissue for control in this systematic review. All the eligible studies were published between 2012 and 2020.

Study characteristics

All of the studies selected were reviewed and the result were displayed on Table 1. We reviewed the intervention given to the patient, gene expression analysis, and outcomes which was consisted of recurrence and metastasis. Eleven out of 12 studies assessed the recurrence-free survival related to the BCSCs and five studies out of 12 studies assessed the metastasis associated with BCSCs. Only four studies which analyzed both tumor recurrence and metastasis. Only three studies provided data about mean or median follow-up time Table 2.

Association between BCSCs expression with

clinicopathological parameters

We identified several BCSCs in this review, which included SOX2, SOX4, ALDH1, CD44, Nanog, Cripto-1, OCT4, CD133, β -arrestin-1 (ARRB1) and β -arrestin-2 (ARRB2), IGF1R, p-TFCP2L1, and CDK1. Eight out of 12 studies included performed Kaplan-Meier survival analysis to compare the effect of respective BCSCs expression on clinicopathological parameters. All of the gene were found to be significant prognostic factors based on univariate analysis. Moreover, multivariate analysis using Cox regression also showed that the majority of gene expression were independent prognostic factors; thus, it may play a role as a potentially valuable marker in predicting the recurrence-free, metastasis-free, or disease-free (recurrence/metastasis-free) with P<0.05 Table 3.

Table 2. Study characteristics

						Outc	omes	Mean
Study (year)	Design	Participants	Control	Intervention	Gene Expression Analysis	Recurrence	Metastasis	or median follow- up
Ruan et	Case-	32 BCa	32	-	qrtRT-PCR	High SOX2	-	2 years
al., 2012	control	tissues	correspo		IHC	expression		
[6]			nding			significantly played a		
			normal			role in predicting the		
			tissues			recurrence-free		
						survival in T1 BCa		
						patients		

Keymoosi	Prospecti	159 patients	-	TURBT with no	IHC on	High ALDH1 and	-	46
et al.,	ve Cohort	with		prior	TMA slides	CD44 expressions		months
2013 [13]		urothelial		chemotherapy or		were correlated with		
		carcinoma		radiation therapy		a significantly		
						increased rate of		
						recurrence (P=0.013)		
Wei et al.,	Prospecti	130 BCa	-	Cystectomy or	qRT-PCR	High Cripto-1 was	-	Not
2014 [14]	ve cohort	patients		Transurethral	IHC	significantly		availabl
				resection of the		associated with		e
				bladder		expression and tumor		
				tumor.		recurrence or		
						metastasis (P=0.007)		

Senol et	Prospecti	163 cases of	-	-	IHC	ALDH1 expression	-	23.60□
al., 2015	ve cohort	urothelial				was significantly		16.88
[15]		carcinomas				associated with		months
		of the bladder				disease recurrence		
		(UCB)				(P<0.001), however,		
						CD44 was not		
						significantly		
						associated (P=0.688)		
Sedaghat	Retrospec	140 tissues	-	-	TMA-based	OCT4 expression had	-	Not
et al.,	tive	from			IHC	no correlation with		availabl
2016 [2]	cohort	transitional				tumor recurrence		e
		cell				(P=0.32) or CD133		
		carcinoma				(p=0.71)		
		samples						

Siddiqui	Prospecti	112		Bacillus	IHC	High CD44 and	-	Not
et al.,	ve cohort	histopatholog		Calmette Gurein		NANOG expression		availabl
2019 [16]		ically proven		(BCG), non-		were significantly		e
		BCa		BCG, radical		associated with lower		
				cystectomy with		tumor recurrence		
				and without		(P<0.001)		
				adjuvant therapy				
Chiu et	Retrospec	For patients	-	-	IHC staining	High SOX2 and	-	Not
al., 2020	tive	with			with SOX2	IGF1R expression		availabl
[17]	cohort	transitional			antibody	was correlated with		e
		cell				poor recurrence-free		
		carcinoma of				survival and was		
		the urinary				increased in "poorly		
		bladder,				differentiated"		

not specified tumors (P=0.0187)	
Shen et Retrospec 309 patients - IHC High Sox4 High Sox4 N	Not
al., 2015 tive with expression was expression was a	vailabl
[1] cohort transitional significantly e	:
cell associated with associated with	
carcinoma of higher tumor grade invasiveness (more	
the urinary (more likely to likely to spread to	
bladder recurrent). other parts of the	
(P = 3.71E-10)	

							body). (P = 7.00E- 04)	
Xu et al., 2015 [18]	Prospecti ve Cohort	227 patients with bladder urothelial cell carcinoma (118 non- invasive and 109 invasive)	-	118 patients with non-invasive bladder carcinoma: 11 underwent radical cystectomy and 107 underwent	IHC using ALDH1A1 antibody and secondary antibody from EnVision System	ALDH1 expression was significantly associated with tumor recurrence ($P \le 0.05$).	ALDH1 expression was significantly associated with lymph node (P = 0.008) and tumor distant metastases (P = 0.018)	52- months
				intravesical chemotherapy after transurethral resection				

109 patients with invasive disease: 69 underwent radical cystectomy. 20 underwent partial cystectomy; and 20 underwent transurethral
resection

Heo J et	Retrospec	400 patients	-	TURBT	IHC	p-TFCP2L1 and	High levels of co-	Not
al., 2019	tive	with				CDK1 expression	expression of p-	availabl
[19]	cohort	urothelial				were not associated	TFCP2L1 and CDK1	e
		carcinoma				with recurrence	were associated with	
						(P=0.563)	distant metastasis	
							(P=0.442)	
Shaifei et	Case-	472 bladder	16	TURBT with no	IHC on	DCLK1 expression	DCLK1 expression	Not
al., 2019	control	tumors	matched	prior	TMA slides	was not associated	was significantly	availabl
[20]			adjacent	neoadjuvant		with recurrence	associated with	e
			non-	treatment before		(P=0.314)	distant metastasis	
			cancerou	surgery			(P=0.042)	
			s normal					
			tissue					

Kallifatidi	Retrospec	43 bladder	20	Cohort 2	RT-q-PCR		ARRB1 transcript	Not
s et al.,	tive	tumors in	normal	receiving			levels in bladder	availabl
2019 [21]	cohort	cohort 1;	bladder	gemcitabine +			tumor specimens	e
		43 bladder		cisplatin			from patients who	
		tumors in					developed metastasis	
		cohort 2					were 7.7-fold	
							elevated compared to	
							the normal bladder	
							and 5.2-fold elevated	
							compared to BCa	
							specimens from	
							patients who did not	
							develop metastasis	
ICH Im	1 1) AD OFF		1		na miaraarray): aDT DC	D D 1 m' 0	

¹⁶⁴ ICH, Immunohistochemistry; NMIBC, non-muscle-invasive bladder cancer;(tissue microarray); qRT-PCR, Real-Time Quantitative

Reverse Transcription Polymerase Chain Reaction; TURBT, Transurethral Resection of Bladder Tumor

Table 3. Univariate and multivariate analysis of recurrence and metastasis as prognostic factors in patients with bladder carcinoma

Outcome	Gene expression	Study (year)	Univariate analysis		Multivariate analysis	
			HR (95% CI)	P value	HR (95% CI)	P value
Recurrence -free	SOX2	Chiu (2020)	2.467 (1.292-4.709)	0.0062	2.966 (1.451-6.064)	0.0029
		Ruan (2013)	4.2 (1.827-9.654)	0.001	3.187 (1.130-8.990)	0.029
	ALDH1	Xu (2015)	2.84 (1.19-7.14)	0.040	-	-
	CD44/Nanog	Siddiqui (2019)	32.52 (9.79-107.99)	<0.001	25.45 (6.71-96.50)	<0.001
	ALDH1	Senol (2015)	-	-	4.590 (2.042-10.319)	0.001
	CD44		-	-	0.548(0.283-1.059)	0.074
Metastasis	ARRB1	Kallifatidis (2020)	1.35 (1.06-1.71)	0.0137	1.07 (1.01-1.13)	0.015
	ARRB2		0.03 (0.35-0.003)	0.005	0.13 (0.86-0.02)	0.006

Disease- Cripto-1 Wei (2015) 2.678 (1.280-5.605) 0.009 2.306 (1.05)	55-5.039) 0.036
free DCLK1 Shafiei 1.642 (1.063-2.534) 0.025 1.564 (1.063-2.534)	0.048
(recurrence (2019)	
metastasis)	

Discussion

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Cancer cells utilize normal stem cell self-renewal for long-term proliferation and tissue-repair pathways for invasion; therefore, CSCs expression in cancer may be associated with disease prognosis and treatment outcomes. [1] Association between tumor biology and CSCs has been addressed in various types of cancer, including breast cancer, colorectal cancer, and bladder cancer. Many studies have revealed that CSCs were considered as an important factor leading to tumor recurrence and metastatic; however, its exact mechanisms are still unclear and may have a different pathway one to another. [22] By identifying and understanding the molecular mechanism of In recurrent and metastatic BCa, numerous stem cell phenotypes, such as beta arrestins, SOX2, SOX4, transcription factor CP2 like 1 (TFCP2L1), and doublecortin-like kinase 1 (DCLK1), have all been identified and described. Two studies reporting a significant relationship between high expression of SOX2 with poor recurrence-free survival also found that SOX2 was highly expressed in tumors with poor pathological differentiation; thus, marking its role in BCa malignancy. SOX2 plays a role in promoting cell proliferation and enhancing cell survival during low-serum stress. BCa cancer cells' survival and spheroid-forming capability enhancement were induced by AKT phosphorylation due to IGF2/IGF1R induction, which was thought to be involved in molecular mechanism of SOX2 expression leading to poor tumor prognosis. Its mechanism made SOX2 a potential therapeutic target for BCa treatment. [6, 17]

CD44 was one of the most stem cells which has been widely studied and was commonly expressed in BCa with a poor prognosis. Hu *et al.* [19] conducted a meta-analysis about the prognostic value of CD44 expression in BCa and found that CD44 expression may be associated with advanced T stage, tumor grade, and lymph node metastasis, but not with recurrence-free survival and overall survival of the disease. ALDH1 was also commonly reported to be a significant prognostic factor in tumor recurrence and metastasis. Xu *et al.* [18] and Senol *et al.* [15] further conducted univariate and multivariate survival analyses and also observed a statistically significant association between ALDH1 expression and recurrence-free survival (P<0.05). Moreover, Xu *et al.* also found that ALDH1 expression was related to tumor distant metastasis. [18]

An inverse expression of ARRB1 and ARRB2 both significantly correlated with tumor metastasis. Kallifatidis *et al.* [21] conducted univariate and multivariate analysis and found that up-regulation of ARRB1 and down-regulation of ARRB2 both played a role as functional biomarkers to predict metastasis (P<0.05). Kallifatidis *et al.* [21] reported that ARRB2 negatively regulated the activation of STAT3, a transcription factor regulating the self-renewal nature of BCSCs. Conversely, ARRB1 was found to positively regulate BMI-1 and ARRB-1 were linked with poorer prognosis in BCa. [21] Overexpression of DCLK1 which was previously reported to be remarkable in cell progression and metastasis of colorectal cancer, was also found to be a significant prognostic factor on BCa. Multivariate Cox regression analyses conducted by Shafiei *et al.* [20] showed DCLK1 protein expression was an independent prognostic factor to poor disease-specific survival in BCa patients. However, the molecular mechanism of the protein expression was not yet well-established. Cripto-1 or teratocarcinoma-derived growth factor-1 (TDGF-1) was found to

have a significant association with tumor recurrence/metastasis in BCa patients (P=0.007) and also as an independent prognostic factor identified with multivariate Cox regression analysis (P=0.036), which validated its role to be a valuable marker as a disease-free predictor in BCa patients. [14] This systematic review showed that most BCSCs expressions were significantly associated with tumor recurrence and metastasis, suggesting its important role in patients' prognosis. CSC-specific cell-surface markers represent potential therapeutic targets. By knowing stem cell expression in BCa, therapeutic strategies could be set and implemented to improve disease outcomes. However, the mechanism of each CSCs was reported to be different due to its heterogeneity in the level of stem cells. Many cell-surface markers and signaling pathways are distinct in quiescent cells and proliferating cells; thus, microenvironmental interactions can alter stem cells' marker expression and signaling pathways. [1] Therefore, a major consideration for this approach remains the specificity of these markers. [2] In addition, specific CSC phenotypes appear to be correlated with disease outcomes, including risks of recurrence and metastasis. [2] Based on these findings, further studies regarding CSCs, especially their molecular mechanism, are warranted and may have significant contribution to the overall management of BCa. Our study has several limitations. The majority of studies included did not show the mean or median follow-up time to determine the outcome. Each study also had different patients' characteristics, tumors' profiles, and treatment plans, which may also affect the recurrence and metastasis. We only presented a systematic review without further analysis; thus, we only can show that many studies have shown the beneficial impact of identifying

BCSCs, and further studies are required.

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

Larger multicenter studies are needed to assess each factor that contributed to the recurrence and metastasis of BCa. However, statistical analysis sometimes has poor accuracy and is not applicable individually; thus, artificial intelligence has been further developed and may answer this problem. There have been several research that stated that artificial intelligence was believed to accurately predict cancer behavior, overall survival, and disease recurrence on BCa. Furthermore, Artificial intelligence can provide patient-tailored instruments for diagnosing and managing BCa.

Conclusions

The detection of cancer stem cell expression offers a promising modality in predicting the prognosis of BCa. However, much is lacking in the molecular mechanisms underlying these processes. Hence, future research in this area is warranted and may highly contribute to the overall management of BCa.

Funding

This work was supported by Universitas Indonesia for funding this research through PUTI Grant with contract number NKB-1533/UN2.RST/HKP.05.00/2020.

COMPETING INTERESTS The authors declare that there were no competing interests. **Author Contributions** Conceptualization: Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar **Data curation:** Agus Rizal Ardy Hariandy Hamid Formal analysis: Agus Rizal Ardy Hariandy Hamid, Yasmina Zahra Syadza **Investigation:** Chaidir Arif Mochtar Methodology: Yasmina Zahra Syadza, Oliver Emmanuel Yausep, Roberto Bagaskara Indy Christanto Project administration: Bayu Hernawan Rahmat Muharia **Software:** Oliver Emmanuel Yausep, Roberto Bagaskara Indy Christanto **Supervision:** Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar Validation: Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar, Yasmina Zahra Syadza Visualization: Yasmina Zahra Syadza, Bayu Hernawan Rahmat Muharia

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

- 274 Writing Original draft: Yasmina Zahra Syadza, Oliver Emmanuel Yausep, Roberto
- 275 Bagaskara Indy Christanto
- Writing review & editing: Agus Rizal Ardy Hariandy Hamid, Chaidir Arif Mochtar

References

- 1. Shen H, Blijlevens M, Yang N, Frangou C, Wilson KE, Xu B, et al. Sox4 expression
- confers bladder cancer stem cell properties and predicts for poor patient outcome.
- International Journal of Biological Sciences. 2015;11(12):1363–75.
- 281 2. Sedaghat S, Gheytanchi E, Asgari M, Roudi R, Keymoosi H, Madjd Z. Expression of
- Cancer Stem Cell Markers OCT4 and CD133 in Transitional Cell Carcinomas. Applied
- Immunohistochemistry and Molecular Morphology. 2017;25(3):196–202.
- 284 3. Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and
- chemoprevention of bladder cancer. Journal of Oncology. 2011;2011.
- 286 4. Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, et al. Identification,
- molecular characterization, clinical prognosis, and therapeutic targeting of human
- bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the
- 289 United States of America. 2009;106(33):14016–21.
- 5. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion
- and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell
- 292 bladder cancer. Journal of Urology. 1998;159(1):91–4.

- 293 6. Ruan J, Wei B, Xu Z, Yang S, Zhou Y, Yu M, et al. Predictive value of Sox2 expression
- in transurethral resection specimens in patients with T1 bladder cancer. Medical
- 295 Oncology. 2013;30(1).
- 7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem
- 297 cells. Nature. 2001;414(November):105–11.
- 8. Jordan CT, Guzman ML, Noble M. Cancer stem cells. New England Journal of
- 299 Medicine. 2006;355(12):1253-61.
- 300 9. Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, et al. Cancer stem
- 301 cells in solid tumors: An overview and new approaches for their isolation and
- characterization. FASEB Journal. 2013;27(1):13–24.
- 303 10. Li Y, Lin K, Yang Z, Han N, Quan X, Guo X, et al. Bladder cancer stem cells: clonal
- origin and therapeutic perspectives. Oncotarget. 2017;8(39):66668–79.
- 305 11. Abugomaa A, Elbadawy M, Yamawaki H, Usui T, Sasaki K. Emerging Roles of Cancer
- 306 Stem Cells in Bladder Cancer Progression, Tumorigenesis, and Resistance to
- Chemotherapy: A Potential Therapeutic Target for Bladder Cancer. Cells. 2020;9(1):1–
- 308 19.
- 309 12. Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred
- reporting items for systematic reviews and meta-analyses: The PRISMA statement.
- 311 PLoS Medicine. 2009;6(7).
- 13. Keymoosi H, Gheytanchi E, Asgari M, Shariftab A, Madjd Z. ALDH1 in Combination
- with CD44 as Putative Cancer Stem Cell Markers are Correlated with Poor Prognosis

- in Urothelial Carcinoma of the Urinary Bladder. Asian Pac J Cancr Prev.
- 315 2014;15(5):2013–9.
- 316 14. Wei B, Jin W, Ruan J, Xu Z, Zhou Y, Liang J, et al. Cripto-1 expression and its
- prognostic value in human bladder cancer patients. Tumor Biology. 2015 Feb
- 318 27;36(2):1105–13.
- 319 15. Senol S, Yildırım A, Akalin I, Uruç F, Çobanoğlu B, Yilmaz S, et al. Relation of stem
- 320 cell markers ALDH1 and CD44 with clinicopathological factors in urothelial
- carcinomas of urinary bladder [Internet]. Vol. 8, Int J Clin Exp Med. 2015. Available
- from: www.ijcem.com/
- 323 16. Siddiqui Z, Srivastava A, Sankhwar S, Dalela D, Singh V, Zaidi N, et al. Synergic
- effects of cancer stem cells markers, CD44 and embryonic stem cell transcription factor
- Nanog, on bladder cancer prognosis. British Journal of Biomedical Science. 2019;1–7.
- 326 17. Chiu YF, Wu CC, Kuo MH, Miao CC, Zheng MY, Chen PY, et al. Critical role of
- 327 SOX2–IGF2 signaling in aggressiveness of bladder cancer. Scientific Reports. 2020
- 328 Dec 1;10(1).
- 329 18. Xu N, Shao MM, Zhang HT, Jin MS, Dong Y, Ou RJ, et al. Aldehyde dehydrogenase
- 1 (ALDH1) expression is associated with a poor prognosis of bladder cancer. Cancer
- 331 Epidemiology. 2015 Jun 1;39(3):375–81.
- 19. Heo J, Noh B, Lee S, Lee H, Kim Y, Lim J, et al. Phosphorylation of TFCP2L1 by
- CDK1 is required for stem cell pluripotency and bladder carcinogenesis. EMBO
- 334 Molecular Medicine. 2020 Jan 9;12(1).

20. Shafiei S, Kalantari E, Saeednejad Zanjani L, Abolhasani M, Asadi Lari MH, Madjd Z. Increased expression of DCLK1, a novel putative CSC marker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas. Experimental and Molecular Pathology. 2019 Jun 1;108:164–72.
21. Kallifatidis G, Smith DK, Morera DS, Gao J, Hennig MJ, Hoy JJ, et al. B-arrestins regulate stem cell-like phenotype and response to chemotherapy in bladder cancer. Molecular Cancer Therapeutics. 2019 Apr 1;18(4):801–11.
22. Kang Y, Zhu X, Wang X, Liao S, Jin M, Zhang L, et al. Identification and Validation of the Prognostic Stemness Biomarkers in Bladder Cancer Bone Metastasis. Frontiers in Oncology. 2021 Mar 19;11.




Figure 1